MX2024011860A - Inhibidores de tyk2 y usos de los mismos - Google Patents

Inhibidores de tyk2 y usos de los mismos

Info

Publication number
MX2024011860A
MX2024011860A MX2024011860A MX2024011860A MX2024011860A MX 2024011860 A MX2024011860 A MX 2024011860A MX 2024011860 A MX2024011860 A MX 2024011860A MX 2024011860 A MX2024011860 A MX 2024011860A MX 2024011860 A MX2024011860 A MX 2024011860A
Authority
MX
Mexico
Prior art keywords
disorder
tyk2
tyk2 inhibitors
mediated
inhibitors
Prior art date
Application number
MX2024011860A
Other languages
English (en)
Spanish (es)
Inventor
Philip Nunn
Original Assignee
Alumis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alumis Inc filed Critical Alumis Inc
Publication of MX2024011860A publication Critical patent/MX2024011860A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2024011860A 2022-03-29 2024-09-26 Inhibidores de tyk2 y usos de los mismos MX2024011860A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263324754P 2022-03-29 2022-03-29
US202263344126P 2022-05-20 2022-05-20
US202263408572P 2022-09-21 2022-09-21
US202263429720P 2022-12-02 2022-12-02
PCT/US2023/016677 WO2023192351A1 (en) 2022-03-29 2023-03-29 Tyk2 inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
MX2024011860A true MX2024011860A (es) 2024-11-08

Family

ID=86142785

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024011860A MX2024011860A (es) 2022-03-29 2024-09-26 Inhibidores de tyk2 y usos de los mismos

Country Status (11)

Country Link
US (1) US20250205211A1 (enExample)
EP (1) EP4499092A1 (enExample)
JP (1) JP2025510311A (enExample)
KR (1) KR20240166011A (enExample)
CN (1) CN119546299A (enExample)
AU (1) AU2023245329A1 (enExample)
CA (1) CA3246725A1 (enExample)
IL (1) IL315866A (enExample)
MX (1) MX2024011860A (enExample)
TW (1) TW202342000A (enExample)
WO (1) WO2023192351A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121909018A (zh) * 2023-09-20 2026-04-21 阿鲁米斯公司 Tyk2抑制剂的立即释放制剂
WO2026136251A1 (en) * 2024-12-16 2026-06-25 Alumis Inc. Tyk2 inhibitor for treating neuroinflammatory or neurodegenerative diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS66346B1 (sr) 2018-10-22 2025-01-31 Alumis Inc Inhibitori tyk2 i njihova upotreba
US20230295119A1 (en) * 2020-04-14 2023-09-21 Gossamer Bio Services, Inc. Substituted pyridines for the treatment of inflammatory diseases
WO2021237121A1 (en) * 2020-05-21 2021-11-25 Gossamer Bio Services, Inc. Substituted pyridines

Also Published As

Publication number Publication date
KR20240166011A (ko) 2024-11-25
TW202342000A (zh) 2023-11-01
CA3246725A1 (en) 2023-10-05
US20250205211A1 (en) 2025-06-26
IL315866A (en) 2024-11-01
WO2023192351A1 (en) 2023-10-05
EP4499092A1 (en) 2025-02-05
AU2023245329A1 (en) 2024-10-10
CN119546299A (zh) 2025-02-28
JP2025510311A (ja) 2025-04-14

Similar Documents

Publication Publication Date Title
EP4480953A3 (en) Tyk2 inhibitors and uses thereof
MX2024011232A (es) Inhibidores de tyk2 y usos de los mismos
MY205856A (en) Methods of treating cancers and enhancing efficacy of t cell redirecting therapeutics
PH12020551923A1 (en) Methods and compositions for treating cancer
MX2024011231A (es) Inhibidores de tyk2 y usos de los mismos
MX2022012621A (es) Enlazadores de variantes de carga.
SA521430536B1 (ar) مواد مضافة إسمنتية
MX2022005411A (es) COMPUESTOS DE UNIÓN A IL-2RßYC.
MX2022006366A (es) Terapia de combinacion que implica compuestos de diarilo macrociclico.
MX2024001243A (es) Composiciones y metodos para el tratamiento de melanoma.
WO2023064278A3 (en) Compositions and methods that inhibit il-23 signaling
MX2020008867A (es) Método para mejorar el rendimiento de plantas.
WO2022192249A3 (en) Compositions and methods for assessing and treating t cell dysfunction
MX2022010568A (es) Métodos y composiciones que usan nanoportadores sintéticos que comprenden inmunosupresor.
AU2019251289A8 (en) Combination of LIF inhibitors and PD-1 axis inhibitors for use in treating cancer
MX2023008598A (es) Agentes de interleuquina-2 y usos de los mismos.
MX2021008834A (es) Metodos de tratamiento del cancer de mama con tucatinib.
MX2023005180A (es) Compuestos de union a il-2r\03b2?c y usos de estos.
MX2025001406A (es) Metodo para tratar la hipertension con el inhibidor de la aldosterona sintasa baxdrostat
MX2025002689A (es) Sistema y metodos de clasificacion de camarones
WO2020247936A3 (en) Kisspeptins to predict and treat delayed puberty
MX2025012361A (es) Tecnologias dirigidas a estados celulares
MX2025004326A (es) Metodo para preparar maribavir
WO2020215077A3 (en) Stable targeted integration
PH12021552251A1 (en) Methods of treating borderline personality disorder